Stock Performance and Market Context
The stock’s latest peak at Rs. 2,850 represents a new 52-week and all-time high, achieved amid a bullish technical trend that has been in place since early April 2026. On the day of this milestone, the stock recorded a gain of 1.09%, outperforming the Sensex which rose by 0.28%. Over the past five trading sessions, Fredun Pharmaceuticals has delivered a consecutive gain of 13.49%, underscoring consistent buying interest and momentum.
Comparing its performance against broader market indices highlights the stock’s exceptional trajectory. Over one year, Fredun Pharmaceuticals has surged by 245.69%, vastly outpacing the Sensex’s decline of 8.37%. Year-to-date returns stand at 80.26%, while the three-month and one-month performances are 65.77% and 18.72% respectively, both significantly ahead of the Sensex benchmarks. Even over longer horizons, the stock’s five-year return of 586.45% dwarfs the Sensex’s 46.59%, and its ten-year return of 13,447.62% is a testament to its extraordinary growth story.
Technical Indicators and Moving Averages
Fredun Pharmaceuticals is trading comfortably above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, reinforcing the strength of its upward trend. Technical indicators such as MACD, Bollinger Bands, KST, and Dow Theory all signal a bullish outlook on both weekly and monthly timeframes. The immediate support level remains at the 52-week low of Rs. 794, while the stock has decisively surpassed major resistance levels at Rs. 1,798.87 (200 DMA), Rs. 2,030.06 (100 DMA), and Rs. 2,469.52 (20 DMA).
Financial Performance and Growth Metrics
The company’s financials underpin its market success. Fredun Pharmaceuticals has demonstrated healthy long-term growth with net sales expanding at a compound annual growth rate (CAGR) of 36.42% over five years. Operating profit has grown even more robustly at 59.04% CAGR, reflecting operational efficiency and margin improvement. The firm has reported positive results for eight consecutive quarters, with quarterly profit before tax (PBT less other income) reaching Rs. 11.25 crores, a growth of 54.96% year-on-year.
Quarterly profit after tax (PAT) has also hit a record Rs. 10.78 crores, while annual operating cash flow stands at its highest level of Rs. 16.44 crores. Net sales for the latest quarter reached Rs. 213.05 crores, accompanied by a quarterly profit before depreciation, interest, and tax (Pbdit) of Rs. 28.88 crores. These figures illustrate a strong upward trajectory in both top-line and bottom-line performance.
Valuation and Quality Assessment
Fredun Pharmaceuticals currently trades at a price-to-earnings (P/E) ratio of 42x on a trailing twelve months (TTM) basis, with a price-to-book value (P/BV) of 5.58x. The enterprise value to capital employed (EV/CE) ratio stands at an attractive 3.93x, indicating reasonable valuation relative to the company’s capital base. The PEG ratio of 0.72x suggests that the stock’s price growth is supported by earnings growth, reflecting a balanced valuation perspective.
The company’s return on capital employed (ROCE) is a healthy 19.9%, signalling efficient use of capital to generate profits. Dividend yield remains modest at 0.05%, with a recent dividend payout of Rs. 0.7 per share and a payout ratio of 1.15%, consistent with the company’s focus on reinvestment and growth.
Quality assessments rate Fredun Pharmaceuticals as an average quality company based on long-term financial performance. While growth metrics are excellent, capital structure and management risk are assessed as below average and average respectively. The company maintains moderate leverage with a net debt to equity ratio of 0.56 and average debt to EBITDA of 2.93. Importantly, there is no promoter share pledging, and institutional holdings remain low at 3.89%.
Promoter Confidence and Stakeholding
Promoter confidence in Fredun Pharmaceuticals is evident from their increased stake, which rose by 1.11% over the previous quarter to 44.17%. This rise in promoter shareholding is a notable indicator of commitment to the company’s ongoing growth and stability.
Market-Beating Returns Across Timeframes
The stock’s performance has consistently outpaced broader market indices across multiple timeframes. Over the past three years, Fredun Pharmaceuticals has delivered a return of 242.83%, compared to the BSE500’s 18.50%. Its one-year return of 245.69% and three-month return of 65.77% further highlight its ability to generate superior returns relative to the market.
This sustained outperformance is supported by strong fundamentals, improving profitability, and a favourable technical setup, culminating in the recent all-time high price milestone.
Summary
Fredun Pharmaceuticals Ltd’s achievement of an all-time high price of Rs. 2,850 on 01 Jul 2026 marks a significant milestone in its market journey. The company’s robust financial growth, strong quarterly results, attractive valuation metrics, and rising promoter confidence have collectively contributed to this landmark. The stock’s consistent outperformance against major indices and its bullish technical indicators further underscore the strength of its current position within the Pharmaceuticals & Biotechnology sector.
As Fredun Pharmaceuticals continues to trade above key moving averages and maintains positive momentum, this milestone reflects the culmination of years of sustained growth and operational progress.
